GlassScriptPhysician profile
Abigail Cobb
NPI 1558838532
$5,092.21
in general payments reported to CMS, 2019-2025
31 companies · $571 in 2025
The $571 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,119 · 2022: $845 · 2023: $874 · 2024: $682 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,107 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.27 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $837.75 | 2021-2025 | Varithena Administration Pack |
| Astrazeneca Pharmaceuticals LP | $482.41 | 2021-2024 | Farxiga |
| Novo Nordisk INC | $425.87 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $420.88 | 2021-2025 | Verquvo |
| Amgen INC. | $371.53 | 2021-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $286.31 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $267.35 | 2021-2024 | Xarelto |
| Abbott Laboratories | $251.44 | 2021-2024 | Aveir, Jot Dx |
| Amarin Pharma, INC. | $238.68 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.16 | 2021-2023 | Jardiance |
| Cvrx, INC. | $186.64 | 2022-2023 | Barostim Neo System |
| Pfizer INC. | $175.50 | 2021-2025 | |
| Atricure, INC. | $142.02 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $120.79 | 2021-2023 | Lifevest |
| Astellas Pharma US INC | $97.20 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $90.53 | 2024-2025 | Impella |
| Edwards Lifesciences Corporation | $87.84 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Esperion Therapeutics, INC. | $64.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.33 | 2024-2025 | |
| Veryan Medical Incorporated | $39.73 | 2021 | |
| Bard Peripheral Vascular, INC. | $36.36 | 2023-2024 | Venclose Maven Catheter |
| Cardiovascular Systems INC. | $24.42 | 2022 | |
| Kestra Medical Technology Services, INC. | $23.31 | 2024 | Assure Wcd |
| Masimo Corporation | $22.70 | 2022 | |
| Medtronic, INC. | $19.80 | 2024 | Reveal Linq |
| Lantheus Medical Imaging, INC. | $19.23 | 2023 | Definity |
| Glaxosmithkline, LLC. | $17.57 | 2025 | Shingrix, Arexvy |
| Kiniksa Pharmaceuticals, LTD. | $16.69 | 2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $15.51 | 2023 | Camzyos |
| Regeneron Healthcare Solutions, INC. | $14.91 | 2021 | |
| Philips North America LLC | $14.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.